ZA935728B - Glycoforms of soluble complement receptor 1. - Google Patents

Glycoforms of soluble complement receptor 1.

Info

Publication number
ZA935728B
ZA935728B ZA935728A ZA935728A ZA935728B ZA 935728 B ZA935728 B ZA 935728B ZA 935728 A ZA935728 A ZA 935728A ZA 935728 A ZA935728 A ZA 935728A ZA 935728 B ZA935728 B ZA 935728B
Authority
ZA
South Africa
Prior art keywords
glycoforms
scr1
complement receptor
soluble complement
methods
Prior art date
Application number
ZA935728A
Other languages
English (en)
Inventor
Henry C Marsh Jr
Richard A G Smith
Chang-Jing Grace Yeh
John Lifter
Anne Mary Freeman
Michael L Gosselin
Original Assignee
T Cell Sciences Inc
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc, Smithkline Beecham Plc filed Critical T Cell Sciences Inc
Publication of ZA935728B publication Critical patent/ZA935728B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166Streptokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
ZA935728A 1992-08-07 1993-08-06 Glycoforms of soluble complement receptor 1. ZA935728B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/927,099 US5456909A (en) 1992-08-07 1992-08-07 Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo

Publications (1)

Publication Number Publication Date
ZA935728B true ZA935728B (en) 1994-03-03

Family

ID=25454172

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA935728A ZA935728B (en) 1992-08-07 1993-08-06 Glycoforms of soluble complement receptor 1.

Country Status (15)

Country Link
US (3) US5456909A (xx)
EP (1) EP0656061B1 (xx)
JP (1) JP3662250B2 (xx)
CN (1) CN1089951A (xx)
AT (1) ATE253591T1 (xx)
CA (1) CA2141842C (xx)
DE (1) DE69333287T2 (xx)
DK (1) DK0656061T3 (xx)
ES (1) ES2210241T3 (xx)
IL (1) IL106558A (xx)
MX (1) MX9304800A (xx)
PT (1) PT656061E (xx)
TW (1) TW386878B (xx)
WO (1) WO1994003603A1 (xx)
ZA (1) ZA935728B (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
CA2162600C (en) * 1993-05-17 2000-07-11 Chrales W. Rittershaus Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
DE69534701T2 (de) 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
KR100425965B1 (ko) * 1998-02-20 2004-04-06 타녹스 인코퍼레이티드 보체 활성화의 억제물질
SE0004808D0 (sv) * 2000-12-20 2000-12-20 Apbiotech Ab Method for the purification of an enzyme
US20040214228A9 (en) * 2001-09-14 2004-10-28 Ganesh Venkataraman Methods of evaluating glycomolecules for enhanced activities
EP1438387A4 (en) * 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc METHODS OF MAKING GLYCOMOLECULES WITH IMPROVED ACTIVITY, AND USES THEREOF
WO2004094823A2 (en) 2003-04-23 2004-11-04 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
JP4507682B2 (ja) * 2004-04-26 2010-07-21 三菱化学株式会社 糖鎖分離方法、検体分析方法、液体クロマトグラフィー装置、並びに糖鎖分析方法及び糖鎖分析装置
US20090028850A1 (en) * 2004-05-14 2009-01-29 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
US20070004625A1 (en) * 2005-06-30 2007-01-04 Li Liang-Man Use of complement inhibitory proteins to treat spinal cord injury
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
CA2624393C (en) * 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP1969007B1 (en) 2005-12-20 2013-08-28 Bristol-Myers Squibb Company Compositions and methods for producing a composition
WO2007103134A2 (en) * 2006-03-02 2007-09-13 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
HUE026496T2 (en) * 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US7914499B2 (en) 2006-03-30 2011-03-29 Valeritas, Inc. Multi-cartridge fluid delivery device
EP2913342A1 (en) 2006-09-05 2015-09-02 Alexion Pharmaceuticals, Inc. Compositions for use in the treatment of antibody mediated neuropathies
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
MY157948A (en) * 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20120027055A (ko) * 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
CN107661491A (zh) * 2010-09-15 2018-02-06 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
US9649356B2 (en) 2010-10-27 2017-05-16 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type I (sCR1)
EP2686671A4 (en) 2011-03-12 2015-06-24 Momenta Pharmaceuticals Inc N-GLYCANES CONTAINING N-ACETYLHEXOSAMINE IN GLYCOPROTEIN PRODUCTS
WO2013013193A1 (en) * 2011-07-20 2013-01-24 Zepteon, Incorporated Polypeptide separation methods
EP2856159A4 (en) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc METHODS RELATING TO DENOSUMAB
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック, インコーポレイテッド 抗d因子抗体及びコンジュゲート
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US20210238238A1 (en) * 2018-05-16 2021-08-05 Csl Limited Soluble complement receptor type i variants and uses thereof
EP3581203A1 (en) * 2018-06-11 2019-12-18 Laboratoire Français du Fractionnement et des Biotechnologies Antibodies with increased activity in the digestive tract
WO2023240322A1 (en) * 2022-06-17 2023-12-21 CSL Innovation Pty Ltd Purification of soluble complement receptor and variants thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo

Also Published As

Publication number Publication date
US5858969A (en) 1999-01-12
IL106558A0 (en) 1993-12-08
WO1994003603A1 (en) 1994-02-17
AU670453B2 (en) 1996-07-18
CN1089951A (zh) 1994-07-27
CA2141842C (en) 2008-07-29
EP0656061B1 (en) 2003-11-05
DK0656061T3 (da) 2004-03-15
JP3662250B2 (ja) 2005-06-22
ES2210241T3 (es) 2004-07-01
US6057131A (en) 2000-05-02
DE69333287D1 (de) 2003-12-11
MX9304800A (es) 1994-05-31
EP0656061A1 (en) 1995-06-07
IL106558A (en) 1998-10-30
DE69333287T2 (de) 2004-09-23
PT656061E (pt) 2004-03-31
US5456909A (en) 1995-10-10
JPH08501773A (ja) 1996-02-27
ATE253591T1 (de) 2003-11-15
TW386878B (en) 2000-04-11
AU4804193A (en) 1994-03-03
CA2141842A1 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
ZA935728B (en) Glycoforms of soluble complement receptor 1.
KR100206481B1 (en) Galenic form for ocular administration and process for the preparation of same
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
ES8607732A1 (es) Procedimiento para producir un preparado implantable de un peptido regulador, uno de sus analogos o una de sus sales fisiologicamente compatibles.
HUT59000A (en) Process for producing pharmaceutical preparations containing 4-phenyl-1,2,3,4-tetrahydro-1-naphtalinamine-derivatives
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
EP0337256A3 (de) Verfahren zur Herstellung pharmazeutischer Mischungen
MY109143A (en) Sulfonamido-and sulfonamidocarbonylpyridine 2-carboxamides and their pyridine-n-oxides, process for their preparation and their use as pharmaceuticals
GB2151244B (en) Insolubilized biocompatible hyaluronic acid preparations
HUT63063A (en) Process for producing antibodies against cd44 cell surface glycoprotein and immunosuppressant pharmaceutical compositions comprising same
EP0506840A4 (en) Method of treating ocular diseases by periocular administration of cyclosporine a or g
EP0582930A3 (en) Process for the preparation of diarylcarbonates
GR3002659T3 (en) Pharmaceutical composition for treating inflammation in the eye
MY106528A (en) Method of treating impotence.
HU913776D0 (en) Process for the production of heparosane-n,o-sulphates, and medical preparations containing them as active agents
CA2120153A1 (en) Recombinant immunotoxins
GR3006815T3 (xx)
CA2094347A1 (en) A method of producing a factor viii preparation
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
CA2090011A1 (en) Anti-inflammatory factor, method of isolation, and use
EP0336368A3 (en) N2-(1-carboxy-3-phenylpropyl)-l-lysine derivative and process of producing lysinopril using the compound
IL89430A0 (en) Process for the preparation of 4,4'-dibromodiphenyl
ES8307811A1 (es) "procedimiento para la preparacion de nuevas imidazo 1,2-a pirimidinas".
TW372873B (en) A novel anti-neoplastic cytokine
AU5066693A (en) Process for the preparation of 5,6-diacetoxyindole